Targeting histone deacetylase 6 mediates a dual anti‐melanoma effect: Enhanced antitumor immunity and impaired cell proliferation
暂无分享,去创建一个
David M. Woods | D. Woods | K. Smalley | E. Seto | K. Barrios | J. Pinilla-Ibarz | A. Kozikowski | E. Celis | J. Weber | E. Sotomayor | A. Sarnaik | F. Cheng | D. Marante | E. Sahakian | K. Woan | J. Bergman | A. Villagra | C. Lee | Calvin Lee | T. Knox | J. Powers | M. Lienlaf | H. Wang | P. Perez-Villaroel | J. Canales | Edward Seto | Tessa Knox | Karrune V. Woan | Joel A. Bergman | Honghai Wang | Jorge Canales | Javier Pinilla-Ibarz | Esteban Celis
[1] D. Woods,et al. A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs , 2014, The Journal of Immunology.
[2] C. Thompson. Belinostat approved for use in treating rare lymphoma. , 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[3] R. Madan,et al. Nivolumab: promising survival signal coupled with limited toxicity raises expectations. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] P. Atadja,et al. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity , 2013, Melanoma research.
[5] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[6] A. Kozikowski,et al. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. , 2012, Journal of medicinal chemistry.
[7] Jiuhong Kang,et al. Histone deacetylase inhibition by sodium valproate regulates polarization of macrophage subsets. , 2012, DNA and cell biology.
[8] S. Milstien,et al. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy , 2012, Oncogene.
[9] E. Seto,et al. Modulation of antigen‐presenting cells by HDAC inhibitors: implications in autoimmunity and cancer , 2012, Immunology and cell biology.
[10] H. Weir,et al. Melanoma surveillance in the United States: overview of methods. , 2011, Journal of the American Academy of Dermatology.
[11] Kyle V. Butler,et al. Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3+ T-Regulatory Cells , 2011, Molecular and Cellular Biology.
[12] A. Younes,et al. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. , 2011, Blood.
[13] S. Bae,et al. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. , 2011, American journal of translational research.
[14] D. Rigel,et al. Epidemiology of melanoma. , 2010, Seminars in cutaneous medicine and surgery.
[15] F. Marincola,et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. , 2009, Cancer research.
[16] S. Steinberg,et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Mann,et al. Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions , 2009, Science.
[18] John A Thompson,et al. Treatment of metastatic melanoma: an overview. , 2009, Oncology.
[19] A. Kozikowski,et al. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. , 2008, Journal of medicinal chemistry.
[20] T. Tomasi,et al. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells , 2008, Cancer Immunology, Immunotherapy.
[21] R. Johnstone,et al. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents , 2007, Expert review of anticancer therapy.
[22] G. Rabinovich,et al. Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.
[23] Hanlee P. Ji,et al. Multiplexed protein detection by proximity ligation for cancer biomarker validation , 2007, Nature Methods.
[24] E. Olson,et al. Histone Deacetylase 7 Maintains Vascular Integrity by Repressing Matrix Metalloproteinase 10 , 2006, Cell.
[25] T. Tomasi,et al. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. , 2005, International immunology.
[26] F. Sánchez‐Madrid,et al. HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. , 2004, Immunity.
[27] P. Atadja,et al. Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824 , 2004, Cancer Research.
[28] K. Glaser,et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. , 2003, Biochemical and biophysical research communications.
[29] Xiao-Fan Wang,et al. HDAC6 is a microtubule-associated deacetylase , 2002, Nature.
[30] T. Muley,et al. Cytokine secretion: clinical relevance of immunosuppression in non-small cell lung cancer. , 2001, Lung cancer.
[31] F. Garrido,et al. Rexpression of HLA class I antigens and restoration of antigen‐specific CTL response in melanoma cells following 5‐aza‐2′‐deoxycytidine treatment , 2001, International journal of cancer.
[32] M. Pfaffl,et al. A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.
[33] T. Tomasi,et al. Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors1 , 2000, The Journal of Immunology.
[34] Y. Yun,et al. Effects of tetrandrine and fangchinoline on human platelet aggregation and thromboxane B2 formation. , 1999, Journal of ethnopharmacology.
[35] S. Meng,et al. p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells , 1998 .
[36] V. Pang,et al. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens. , 1997, Human gene therapy.
[37] D. Ruiter,et al. MHC antigens in human melanomas. , 1991, Seminars in cancer biology.
[38] A. Daar,et al. The membrane antigens of human colorectal cancer cells: demonstration with monoclonal antibodies of heterogeneity within and between tumours and of anomalous expression of HLA-DR. , 1983, European journal of cancer & clinical oncology.
[39] D. Buglio,et al. Hodgkin lymphoma HDAC11 plays an essential role in regulating OX40 ligand expression in , 2013 .
[40] T. Tomasi,et al. Histone deacetylase regulation of immune gene expression in tumor cells , 2008, Immunologic research.
[41] Chunlei Zhang,et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.
[42] Ronald Breslow,et al. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.
[43] S. Minucci,et al. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.
[44] S. Meng,et al. WAF 1 is required for butyrate-mediated growth inhibition of human colon cancer cells , 1998 .
[45] T. Iijima,et al. Expression of MHC class II antigens in human lung cancer cells , 1991, Virchows Archiv. B, Cell pathology including molecular pathology.
[46] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.